Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ArrayCGH-based classification of neuroblastoma into genomic subgroups.

Evi Michels1, Jo Vandesompele, Katleen De Preter

  • 1Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.

Genes, Chromosomes & Cancer
|September 8, 2007
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proposal of a Risk Stratification Algorithm for Extracranial Malignant Rhabdoid Tumors.

Cancer medicine·2026
Same author

circVDJ-seq for T cell clonotype detection in single-cell and spatial multi-omics.

Genome medicine·2026
Same author

Single-EV Analyses Require Rigorous Antibody Qualification: PD-L1 Profiling in Cell Models and Patient Plasma.

Journal of extracellular biology·2026
Same author

A pilot study combining primary busulfan-based haploidentical stem cell transplantation with GD2 antibody to treat high-risk neuroblastoma.

Bone marrow transplantation·2026
Same author

Patient Satisfaction and Supportive Care Pathways in a German Head and Neck Tumor Center: A Prospective Cross-Sectional Study.

Healthcare (Basel, Switzerland)·2026
Same author

Comprehensive molecular analyses for diagnosis and treatment guidance in an adult neuroblastoma patient.

The oncologist·2026
Same journal

Biphenotypic Sinonasal Sarcoma With a Novel PAX3::MAML2 Fusion.

Genes, chromosomes & cancer·2026
Same journal

An Affordable and Efficient In-House Approach for Detecting Gene Fusions in Bone and Soft Tissue Tumors Using a Custom Capture Panel and Nanopore Sequencing.

Genes, chromosomes & cancer·2026
Same journal

PKMYT1 in Cancer: Beyond Cell Cycle Checkpoints to Context-Dependent Therapeutic Vulnerability.

Genes, chromosomes & cancer·2026
Same journal

Associations of Dietary Intake Traits and Aging Indicators With Colorectal Cancer: A Mendelian Randomization Study.

Genes, chromosomes & cancer·2026
Same journal

Primary Tumor-Associated Loss of the Y Chromosome and Clinical Outcome in Metastatic Colorectal Cancer.

Genes, chromosomes & cancer·2026
Same journal

Cytogenetic and Molecular Analysis of a "Double-Hit" RUNX1 Including a RUNX1 p.Trp279* and a Cryptic Novel t(6;21)(q25;q22)/RUNX1::ARID1B in Acute Myeloid Leukemia.

Genes, chromosomes & cancer·2026
See all related articles
This summary is machine-generated.

High-resolution genomic profiling reveals distinct neuroblastoma subclasses, aiding in understanding tumor heterogeneity. This analysis identifies 1q gain as a marker for therapy failure in specific subtypes.

Area of Science:

  • Genomics
  • Oncology
  • Molecular Biology

Background:

  • Neuroblastoma exhibits significant genetic heterogeneity, complicating accurate subclassification and prognostication.
  • Existing genomic classifications may not fully capture the spectrum of neuroblastoma's genetic alterations.

Purpose of the Study:

  • To refine genomic subclassification of neuroblastoma using high-resolution array comparative genomic hybridization (arrayCGH).
  • To identify novel genomic subclasses and prognostically relevant alterations in neuroblastoma.

Main Methods:

  • Genome-wide copy number profiling of 75 primary neuroblastoma tumors and 29 cell lines using arrayCGH.
  • Application of a novel data-mining strategy to delineate genomic subclasses.
  • Analysis of genomic imbalances for association with clinical subtypes and prognostic significance.

Related Experiment Videos

Main Results:

  • Three major and two minor genomic subclasses were identified, with 83% of tumors assigned to major subclasses aligning with known clinical subsets.
  • Tumors with atypical genomic alterations, including 11q13 amplification, were identified.
  • 1q gain was identified as a predictive marker for therapy failure in subtype 2A and 2B neuroblastomas.
  • A common region of 6q loss (3.87-5.32 Mb within 6q25.1-6q25.2) was observed in cell lines.

Conclusions:

  • Genomic profiling is crucial for understanding neuroblastoma heterogeneity and refining subclassification.
  • Genome-wide assessment of copy number alterations should be integrated into neuroblastoma diagnostics.
  • Further multicentric studies are needed to improve therapeutic stratification by combining genomic data with clinical and gene expression features.